Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;30(1):11-9.
doi: 10.1016/j.blre.2015.07.001. Epub 2015 Jul 14.

The prothrombotic activity of cancer cells in the circulation

Annachiara Mitrugno  1 , Garth W Tormoen  2 , Peter Kuhn  3 , Owen J T McCarty  4
Affiliations
Review

The prothrombotic activity of cancer cells in the circulation

Annachiara Mitrugno et al. Blood Rev. 2016 Jan.

Abstract

The hemostatic system is often subverted in patients with cancer, resulting in life-threatening venous thrombotic events. Despite the multifactorial and complex etiology of cancer-associated thrombosis, changes in the expression and activity of cancer-derived tissue factor (TF) - the principle initiator of the coagulation cascade - are considered key to malignant hypercoagulopathy and to the pathophysiology of thrombosis. However, many of the molecular and cellular mechanisms coupling the hemostatic degeneration to malignancy remain largely uncharacterized. In this review we discuss some of the tumor-intrinsic and tumor-extrinsic mechanisms that may contribute to the prothrombotic state of cancer, and we bring into focus the potential for circulating tumor cells (CTCs) in advancing our understanding of the field. We also summarize the current status of anti-coagulant therapy for the treatment of thrombosis in patients with cancer.

Keywords: Cancer; Circulating tumor cells; Coagulation; Platelets; Thrombosis; Tissue factor.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. The procoagulant phenotype of circulating tumor cells
In CTC, the expression of the procoagulant protein TF can be enhanced by intrinsic and extrinsic cellular routes. The intrinsic route includes the mutated activity of tumor suppressors (p53 and PTEN) and/or oncogenes (kRAS and MET) that aberrantly induce the transcription and translation of the TF gene. The extrinsic route is initiated outside the cell by TGFβ paracrine signaling, thereby dependent on the EMT program. The TF cytoplasmic domain is linked to a variety of signal transduction proteins (e.g., PI3K and MAPK) that become activated following cell intravasation to prevent anoikis. At the same time, the ectodomain of TF on the CTC surface or on shed tumor-derived microparticles (MPs) initiates the extrinsic coagulation cascade leading to thrombin generation and thus, fibrin formation and platelet activation.
FIGURE 2
FIGURE 2. Coagulation and platelet activation support tumor metastasis
CTCs activate and aggregate platelets via paracrine and/or juxtacrine signals to ensure their survival in the bloodstream and to permit extravasation, proliferation and angiogenesis at the metastatic site. Aggregated platelets and fibrin surround and protect CTCs from NK-mediated lysis via physical shielding. Platelets also release TGFβ and PDGF, which function as downregulators of the NK-activating receptor NKGD. In addition, CTCs can escape the immune surveillance through molecular mimicry of platelets. Tumor cell interaction with the endothelium is thought to be mediated by platelets, specifically via P-selectin binding to PSGL-1 and integrin-fibrinogen-integrin bridges. Platelet release of growth and angiogenic factors (e.g., PDGF, TGFβ, VEGF) as well as proteases (e.g., MMPs) and adenine nucleotides (e.g., ATP) contribute to cancer cell extravasation and formation of new stable capillaries at the metastatic site. Moreover, intracellular signaling transduced via molecules downstream of TF has several benefits for tumor progression (Yellow Box).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine Delivered at the Hotel-Dieu. 1865:281–332.
    1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50. - PubMed
    1. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–91. - PubMed
    1. Williams JC, Mackman N. Tissue factor in health and disease. Front Biosci. 2012;4:358–72. - PubMed
    1. Kasthuri RS, Glover SL, Boles J, Mackman N. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost. 2010;36(7):764–71. - PMC - PubMed

Publication types

MeSH terms